<<RVNC will probably have to do something late Q4 or early Q1. >>
Any chance their burn rate declines from $30 million or so a quarter now that the Sakura trials, with thousands of patients, are mostly or completely done? I understand they will move on to other indications.
RVNC will probably have to [raise capital] late Q4 or early Q1.
The $30M up-front from Fosun equates to roughly four months of op-ex at the current burn rate, which probably allows RVNC to defer a capital raise until they submit the RT002 BLA in 1H19. At that point, a raise will presumably be at a higher share price.
Including the $30M from Fosun, RVNC’s pro forma cash balance at 9/30/18 is about $220M (#msg-144654901).
Market Data 
Markets 
AI
